Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
暂无分享，去创建一个
C. Sotiriou | D. Larsimont | M. Piccart | F. Cardoso | L. Dirix | J. Canon | M. Paesmans | V. D’Hondt | V. Durbecq | G. Jerusalem | V. Cocquyt | P. Delrée | A. Di Leo | J. Demol | A. Vindevoghel | J. Leroy | V. Richard | M. Borms | R. Giuliani | J. Kains | F. Majois | M. Reginster | C. Keppens | V. D'Hondt